Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
25.79
-1.40 (-5.15%)
At close: Oct 16, 2025, 4:00 PM EDT
26.00
+0.21 (0.81%)
After-hours: Oct 16, 2025, 5:23 PM EDT
Beam Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts that cover Beam Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $49.4, which forecasts a 91.55% increase in the stock price over the next year. The lowest target is $21 and the highest is $80.
Price Target: $49.4 (+91.55%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Beam Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 4 | 4 | 4 | 4 | 3 | 4 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +210.20% | Oct 10, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $48 → $46 | Buy | Maintains | $48 → $46 | +78.36% | Oct 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +210.20% | Sep 15, 2025 |
| Barclays | Barclays | Hold Maintains $25 → $21 | Hold | Maintains | $25 → $21 | -18.57% | Aug 6, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $78 → $55 | Strong Buy | Maintains | $78 → $55 | +113.26% | May 7, 2025 |
Financial Forecast
Revenue This Year
42.90M
from 63.52M
Decreased by -32.46%
Revenue Next Year
51.03M
from 42.90M
Increased by 18.95%
EPS This Year
-4.42
from -4.58
EPS Next Year
-4.51
from -4.42
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 69.2M | 115.5M | |||
| Avg | 42.9M | 51.0M | |||
| Low | 15.7M | 29.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 8.9% | 169.2% | |||
| Avg | -32.5% | 18.9% | |||
| Low | -75.3% | -31.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.97 | -3.16 | |||
| Avg | -4.42 | -4.51 | |||
| Low | -4.82 | -5.97 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.